Send to

Choose Destination
See comment in PubMed Commons below
Br J Cancer. 2011 Mar 29;104(7):1067-70. doi: 10.1038/bjc.2011.76. Epub 2011 Mar 8.

Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours.

Author information

  • 1University Department of Medical Oncology, Cancer and Haematology Centre, Churchill Hospital, Headington OX3 7LJ, UK.



This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic neuroendocrine tumours (NETs).


Multicentre phase II, first-line study design. Oral capecitabine was administered on days 1-14 of 3-week cycles.


Treatment was safe and well tolerated. Common toxicities were diarrhoea and fatigue.


The study provides evidence to support the use of capecitabine as a substitute for infusional 5FU in the management of NETs.

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Write to the Help Desk